1. Scrip

Seattle Buys Into Future of Genmab ADC Deal

 
• By Lubna Ahmed

In a six-year-old collaboration with Genmab, Seattle Genetics has decided to exercise its option to co-develop and co-commercialize tisotumab vedotin, an antibody-drug conjugate for solid tumors, granting both companies a 50:50 share.

Digital illustration of Cancer cell in colour background

Seattle Genetics Inc. has decided to exercise its option to co-develop tisotumab vedotin, an antibody-drug conjugate (ADC) currently in Phase I/II trials for solid tumors, under a six-year-old collaboration with Genmab AS. Both companies will now equally share future costs and profits for the product, giving Seattle rights to commercialize in the US, Canada and Mexico and Genmab the remaining territories.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

In Brief: AbbVie’s Rinvoq Secures US Approval For Giant Cell Arteritis

 
• By Sushmita Panda

JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.

CSPC’s Global-First Monospecific ADC Promising In Advanced NSCLC

 
• By Xu Hu

CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.

Abeona Sets $3.1m Price For Rare Skin Disorder Gene Therapy

 
• By Joseph Haas

Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.